All Stories

  1. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer
  2. PCSK6: The Endogenous PAR-1 Agonist Driving Pulmonary Fibrosis?
  3. C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC
  4. C/EBPδ Suppresses Motility-Associated Gene Signatures and Reduces PDAC Cell Migration
  5. Myeloid DNA methyltransferase3b deficiency aggravates pulmonary fibrosis by enhancing profibrotic macrophage activation
  6. Cathepsin S Contributes to Lung Inflammation in Acute Respiratory Distress Syndrome
  7. Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview
  8. Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner
  9. CEBPD Potentiates the Macrophage Inflammatory Response but CEBPD Knock-Out Macrophages Fail to Identify CEBPD-Dependent Pro-Inflammatory Transcriptional Programs
  10. Non-Tumor CCAAT/Enhancer-Binding Protein Delta Potentiates Tumor Cell Extravasation and Pancreatic Cancer Metastasis Formation
  11. ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer
  12. Protease‐activated receptor 1 drives and maintains ductal cell fates in the premalignant pancreas and ductal adenocarcinoma
  13. Alveolar epithelial TET2 is not involved in the development of bleomycin‐induced pulmonary fibrosis
  14. Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-α secretion
  15. Thrombin-mediated vasculogenic mimicry: important lessons to improve anticoagulant therapy of selected cancer patients
  16. CCAAT/Enhancer-Binding Protein Delta (C/EBPδ): A Previously Unrecognized Tumor Suppressor that Limits the Oncogenic Potential of Pancreatic Ductal Adenocarcinoma Cells
  17. Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance?
  18. Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?
  19. Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?
  20. Pharmacological PAR‐1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy
  21. Smoothened-dependent and -independent pathways in mammalian noncanonical Hedgehog signaling
  22. Is idiopathic pulmonary fibrosis a cancer-like disease? Transcriptome analysis to fuel the debate
  23. Protease‐activated receptor‐1 impedes prostate and intestinal tumor progression in mice: comment
  24. Protease-activated receptor-1 contributes to renal injury and interstitial fibrosis during chronic obstructive nephropathy
  25. Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma
  26. PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer
  27. Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
  28. Protease-Activated Receptor 2 Facilitates Bacterial Dissemination in Pneumococcal Pneumonia
  29. Plasmin reduces fibronectin deposition by mesangial cells in a protease-activated receptor-1 independent manner
  30. Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer
  31. Targeting coagulation factor receptors – protease‐activated receptors in idiopathic pulmonary fibrosis
  32. Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer
  33. Dabigatran Potentiates Gemcitabine-Induced Growth Inhibition of Pancreatic Cancer in Mice
  34. Detrimental role for CCAAT/enhancer binding protein δ in blood-borne brain infection
  35. Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice
  36. High endogenous activated protein C levels attenuates bleomycin‐induced pulmonary fibrosis
  37. CCAAT/enhancer-binding protein δ (C/EBPδ) aggravates inflammation and bacterial dissemination during pneumococcal meningitis
  38. Lipid droplets hypertrophy: a crucial determining factor in insulin regulation by adipocytes
  39. Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis
  40. Authors' reply-Re: Shi et al. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. J Pathol 2014;234: 398-409
  41. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model
  42. Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance
  43. The anti-coagulants ASIS or APC do not protect against renal ischemia/ reperfusion injury
  44. The Effect of Levothyroxine on Expression of Inflammation-Related Genes in Healthy Subjects: A Controlled Randomized Crossover Study
  45. CCAAT-enhancer binding protein delta (C/EBPδ) attenuates tubular injury and tubulointerstitial fibrogenesis during chronic obstructive nephropathy
  46. Protease‐activated receptor‐2 induces migration of pancreatic cancer cells in an extracellular ATP‐dependent manner
  47. Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis
  48. Correction for Duitman et al., CCAAT/enhancer-binding protein δ facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner
  49. Protease-Activated Receptor (PAR)2, but Not PAR1, Is Involved in Collateral Formation and Anti-Inflammatory Monocyte Polarization in a Mouse Hind Limb Ischemia Model
  50. CCAAT/enhancer-binding protein delta (C/EBPδ) plays a minor role in renal host defense against uropathogenicEscherichia coli
  51. CCAAT/Enhancer-Binding Protein δ
  52. Irradiated Riboflavin Diminishes the Aggressiveness of Melanoma In Vitro and In Vivo
  53. CCAAT-Enhancer Binding Protein Delta (C/EBPδ) Protects Against Klebsiella pneumoniae–Induced Pulmonary Infection: Potential Role for Macrophage Migration
  54. Characterization of coagulation factor synthesis in nine human primary cell types
  55. Violacein Induces Death of Resistant Leukaemia Cells via Kinome Reprogramming, Endoplasmic Reticulum Stress and Golgi Apparatus Collapse
  56. Protease-activated receptor-4 deficiency does not protect against bleomycin-induced pulmonary fibrosis in mice: Figure 1–
  57. Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology?
  58. Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors
  59. The Acute-phase Response Is Not Predictive for the Development of Arthritis in Seropositive Arthralgia – A Prospective Cohort Study
  60. CCAAT/enhancer-binding protein δ facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner
  61. The protein C pathway in cancer metastasis
  62. Dichotomy in Hedgehog Signaling between Human Healthy Vessel and Atherosclerotic Plaques
  63. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain
  64. Endogenous activated protein C is essential for immune-mediated cancer cell elimination from the circulation
  65. Tissue Factor-Dependent Chemokine Production Aggravates Experimental Colitis
  66. mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome
  67. Blood coagulation factor Xa as an emerging drug target
  68. The Role of Coagulation in Chronic Inflammatory Disorders: A Jack of All Trades
  69. Protease-Activated Receptor-2 Induces Myofibroblast Differentiation and Tissue Factor Up-Regulation during Bleomycin-Induced Lung Injury
  70. Human Plasma Very Low Density Lipoprotein Carries Indian Hedgehog
  71. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells
  72. Assessing the efficacy of the Hedgehog pathway inhibitor vitamin D3 in a murine xenograft model for pancreatic cancer
  73. A Low Molecular Weight Heparin Inhibits Experimental Metastasis in Mice Independently of the Endothelial Glycocalyx
  74. Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation
  75. Canonical Hedgehog signaling drives proangiogenic responses in endothelial cells
  76. The role of activated protein C in cancer progression
  77. Experimental and clinical effects of anticoagulants on cancer progression
  78. The Hedgehog morphogen in myocardial ischemia–reperfusion injury
  79. Prophylactic plasma levels of the low molecular weight heparin nadroparin does not affect colon cancer tumor development in mouse liver
  80. Protease-Activated Receptor 2 Blocking Peptide Counteracts Endotoxin-Induced Inflammation and Coagulation and Ameliorates Renal Fibrin Deposition in a Rat Model of Acute Renal Failure
  81. Additional value of procalcitonin for diagnosis of infection in patients with fever at the emergency department
  82. PTX3 predicts severe disease in febrile patients at the emergency department
  83. Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir
  84. The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm
  85. Alternatively spliced tissue factor induces angiogenesis through integrin ligation
  86. Insider access: pepducin symposium explores a new approach to GPCR modulation
  87. Letter in response to 'Coagulation and fibrosis in chronic liver disease'
  88. Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus
  89. Long‐term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis
  90. Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1–mediated vascular endothelial barrier enhancement
  91. Corrigendum
  92. Activated Protein C Protects Against Myocardial Ischemia/ Reperfusion Injury via Inhibition of Apoptosis and Inflammation
  93. Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation
  94. C-Reactive Protein Elicits White Blood Cell Activation in Humans
  95. Gross deletions/duplications in PROS1 are relatively common in point mutation-negative hereditary protein S deficiency
  96. A mechanism for thrombin-dependent lung metastasis in patients with osteosarcoma
  97. FXa-induced intracellular signaling links coagulation to neoangiogenesis: Potential implications for fibrosis
  98. Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity
  99. Active site inhibited factor VIIa attenuates myocardial ischemia/reperfusion injury in mice
  100. Coagulation factor Xa signaling: the link between coagulation and inflammatory bowel disease?
  101. Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung
  102. Gene Expression Profiles in Murine Influenza Pneumonia
  103. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease
  104. Gene expression profile comparison of Barrett's esophagus epithelial cell cultures and biopsies
  105. Hypoxia induces a hedgehog response mediated by HIF‐1α
  106. TF:FVIIa‐specific activation of CREB upregulates proapoptotic proteins via protease‐activated receptor‐2
  107. Endogenous Hedgehog Expression Contributes to Myocardial Ischemia-Reperfusion–Induced Injury
  108. Leukotriene Synthesis Is Required for Hedgehog‐Dependent Neurite Projection in Neuralized Embryoid Bodies but Not for Motor Neuron Differentiation
  109. Differential Gene Expression Changes in Children with Severe Dengue Virus Infections
  110. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders
  111. Factor Xa Stimulates Proinflammatory and Profibrotic Responses in Fibroblasts via Protease-Activated Receptor-2 Activation
  112. High factor VIIa levels do not promote tumor metastasis
  113. (Pro-)vitamin D as treatment option for hedgehog-related malignancies
  114. Sonic hedgehog induces transcription-independent cytoskeletal rearrangement and migration regulated by arachidonate metabolites
  115. Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation
  116. Hyperglycemia accelerates arterial thrombus formation and attenuates the antithrombotic response to endotoxin in mice
  117. Gene Expression Profiling Identifies C/EBPδ as a Candidate Regulator of Endotoxin-induced Disseminated Intravascular Coagulation
  118. Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation
  119. Colon cancer metastasis in mouse liver is not affected by hypercoagulability due to Factor V Leiden mutation
  120. Protease-Activated Receptors, Apoptosis and Tumor Growth
  121. Factor V Leiden and the etiology of inflammatory bowel disease
  122. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment
  123. Hedgehog Morphogen in Cardiovascular Disease
  124. A dual role for 7-dehydrocholesterol reductase in regulating Hedgehog signalling?
  125. Hedgehog Turns Lipoproteins Into Janus-Faced Particles
  126. Nuclear Receptors Nur77, Nurr1, and NOR-1 Expressed in Atherosclerotic Lesion Macrophages Reduce Lipid Loading and Inflammatory Responses
  127. Toll-like receptor mRNA levels in alveolar macrophages after inhalation of endotoxin
  128. Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice*
  129. Signal transduction induced by activated protein C: no role in protection against sepsis?
  130. Repression of Smoothened by Patched-Dependent (Pro-)Vitamin D3 Secretion
  131. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia*
  132. Alternatively spliced tissue factor in mice: induction by Streptococcus pneumoniae
  133. Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells
  134. Role of coagulation FVIII in septic peritonitis assessed in hemophilic mice
  135. Editorial [Hot Topic: Understanding and Treatment of Diseases in the Haemostatic System (Guest Editor: M.P. Peppelenbosch Co-Editor: C.A. Spek)]
  136. Functional Evolution of Tissue Factor, the Archetype of the Cytokine Receptor Family
  137. Inherited Coagulation Factor VII and X Deficiencies Associated with Severe Bleeding Diathesis: Molecular Genetics and Pathophysiology
  138. RNA-Based Gene Therapy for Haemophilia B
  139. Antiinflammatory Effects of Salmeterol after Inhalation of Lipopolysaccharide by Healthy Volunteers
  140. Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohn’s disease patients
  141. Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation*
  142. High throughput mRNA profiling highlights associations between myocardial infarction and aberrant expression of inflammatory molecules in blood cells
  143. Blood coagulation factors as inflammatory mediators
  144. Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice
  145. Inhibition of the Tissue Factor/Factor VIIa Pathway Does Not Influence the Inflammatory or Antibacterial Response to Abdominal Sepsis Induced byEscherichia coliin Mice
  146. Tissue factor
  147. FVIIa:TF Induces Cell Survival via G 12 /G 13 -Dependent Jak/STAT Activation and Bcl XL Production
  148. Concerted action of coagulation factors on cell survival
  149. Blood cell-derived tissue factor influences host response during murine endotoxemia
  150. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis
  151. Hedgehog: an unusual signal transducer
  152. Tissue Factor and Cancer Metastasis: The Role of Intracellular and Extracellular Signaling Pathways
  153. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways
  154. Functional thrombomodulin deficiency causes enhanced thrombus growth in a murine model of carotid artery thrombosis
  155. Regulation of the p21Ras-MAP kinase pathway by factor VIIa
  156. Tissue factor signal transduction in angiogenesis
  157. Effects of IC14, an Anti‐CD14 Antibody, on Coagulation and Fibrinolysis during Low‐Grade Endotoxemia in Humans
  158. Disseminated intravascular coagulation
  159. Type I diabetes: a role for tissue factor in pancreatic islet transplantation?
  160. Microvascular coagulopathy and disseminated intravascular coagulation
  161. Genetic Risk Factors for Venous Thrombosis
  162. Type-I Protein-C Deficiency Caused by Disruption of a Hepatocyte Nuclear Factor (HNF)-6/HNF-1 Binding Site in the Human Protein-C Gene Promoter
  163. Identification of Evolutionarily Invariant Sequences in the Protein C Gene Promoter
  164. Type I Protein C Deficiency Caused by Disruption of a Hepatocyte Nuclear Factor (HNF)-6/HNF-1 Binding Site in the Human Protein C Gene Promoter
  165. Two Mutations in the Promoter Region of the Human Protein C Gene Both Cause Type I Protein C Deficiency by Disruption of Two HNF-3 Binding Sites
  166. Genotypic Variation in the Promoter Region of the Protein C Gene Is Associated With Plasma Protein C Levels and Thrombotic Risk